Price
$0.15
Increased by 0.00%
Dollar volume (20D)
39.70 K
ADR%
35.24
Shares float
13.04 M
Shares short
5.61 K [0.04%]
Shares outstanding
0.00
Market cap
48.08 M
Beta
1.91
Price/earnings
N/A
20D range
0.11 0.40
50D range
0.11 1.03
200D range
0.11 2.60

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies.

It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor.

It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.

The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT.

BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 0.00
Decreased by N/A%
-2.42 M
Increased by +86.23%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-2.42 M
Increased by +84.64%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-4.37 M
Decreased by -298.62%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-11.88 M
Decreased by -1.43 K%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-17.56 M
Decreased by -2.07 K%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-15.75 M
Decreased by -757.61%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
2.20 M
Increased by +1.12 K%
Increased by +N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
891.04 K
Increased by +280.93%
Increased by +N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY